IP Library Granted Patent US 11,065,335
Granted Patent B2
US 11,065,335 · App. 16/508,630 · Granted Jul 20, 2021

Methods of treating leukemia using compositions containing bis(benzylthio)octanoic acid and ion pairs thereof

Inventors: Robert G. L. Shorr (Edison, NJ); Robert J. Rodriguez (West Windsor, NJ); Rajinder Bhasin (Coram, NY)
Assignee: Rafael Pharmaceuticals, Inc.
A61K47/18A61K31/19A61K31/20A61K31/381A61K45/06A61K47/22A61K47/36A61K47/541Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,065,335
App. No.
16/508,630
Granted
Jul 20, 2021
Kind
B2
Abstract

Pharmaceutical formulations containing lipoic acid derivatives and ion pairs thereof are described. The pharmaceutical formulations are useful in the treatment of medical disorders, such as cancer.

Claims (4)

1. A method of treating leukemia in a human patient in need thereof, comprising the step of intravenously administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of 6,8-bis(benzylthio)octanoic acid or an ion pair thereof, and a pharmaceutically acceptable diluent for solubilizing 6,8-bis(benzylthio)octanoic acid or an ion pair thereof, wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered at a dose of 2,500 mg/m 2 .

2. The method of claim 1 , wherein the pharmaceutically acceptable diluent is a dextrose solution.

3. A method of treating leukemia in a human patient in need thereof, comprising the step of intravenously administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of 6,8-bis(benzylthio)octanoic acid or an ion pair thereof, and a pharmaceutically acceptable aqueous diluent for solubilizing 6,8-bis(benzylthio)octanoic acid or an ion pair thereof, wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered at a dose of 2,500 mg/m 2 .

4. The method of claim 3 , wherein the pharmaceutically acceptable aqueous diluent is a dextrose solution.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2019
From: SHORR, ROBERT G.L.; RODRIGUEZ, ROBERT J.; BHASIN, RAJINDER
To: CORNERSTONE PHARMACEUTICALS, INC.
Reel/Frame 050487/0001 →
CHANGE OF NAME Recorded Sep 25, 2019
From: CORNERSTONE PHARMACEUTICALS, INC.
To: RAFAEL PHARMACEUTICALS, INC.
Reel/Frame 050490/0104 →
Continuity (8)
Continuation 16039799 · Jul 19, 2018
Continuation 15662612 · Jul 28, 2017
Continuation 14857192 · Sep 17, 2015
Continuation 13569654 · Aug 8, 2012
Continuation 12604763 · Oct 23, 2009
Continuation In Part 12105100 · Apr 17, 2008
Provisional Application 60912605 · Apr 18, 2007
Related Publication 20200009254A1 · Jan 9, 2020